Singapore markets close in 8 hours

Nuvation Bio Inc. (NUVB)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
3.4700-0.0800 (-2.25%)
At close: 04:00PM EDT
3.3700 -0.10 (-2.88%)
After hours: 05:32PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.5500
Open3.5200
Bid3.1700 x 1800
Ask3.3700 x 800
Day's range3.4300 - 3.6000
52-week range3.2500 - 10.4500
Volume1,210,930
Avg. volume979,317
Market cap756.908M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.4200
Earnings date10 Aug 2022 - 15 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.67
  • Business Wire

    Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors

    NEW YORK, June 27, 2022--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the Food and Drug Administration (FDA) has placed a partial clinical hold on the Company’s Phase 1 dose escalation study of NUV-422 in solid tumors, including high grade glioma, HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer. The Company’s Phas

  • Business Wire

    Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update

    NEW YORK, May 09, 2022--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the first quarter ended March 31, 2022, and provided a business update.

  • Business Wire

    Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

    NEW YORK, February 28, 2022--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.